Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

A. Emens, Leisha; Cruz, Cristina; P. Eder, Joseph; Braiteh, Fadi; T. Chung, Cathie; M. Tolaney, Sara; Kuter, Irene; Nanda, Rita; A. Cassier, Philippe; Delord, Jean‐Pierre; S. Gordon, Michael; A. ElGabry, Ehab; Chang, Ching-Wei; Sarkar, Indrani; Grossman, William; O’Hear, Carol; Fassò, Marcella; Molinero, Luciana; Schmid, Peter

doi:10.1001/jamaoncol.2018.4224

Public

Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer

Published in JAMA Oncology • Sep 18, 2018

Authors:

Leisha A. Emens

Cristina Cruz

Joseph P. Eder

Abstract

Importance: Atezolizumab (anti-programmed cell death ligand 1 [PD-L1]) is well tolerated and clinically active in multiple cancer types. Its safety and clinical activity in metastatic triple-negative breast cancer (mTNBC) has not been reported. Objective: To evaluate the safety, clinical activity, a...

Subject

Atezolizumab

Medicine

Tolerability

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!